Karyopharm grants retention equity awards: 412,500 stock options and 206,250 RSUs to three executives

Karyopharm Therapeutics Inc.

Named executives Sohanya Chang, Stuart Poulton, and Reshma Rangwala each receive 137,500 options and 68,750 RSUs, effective Feb 28, 2025.
Options vest 25% on first anniversary, then monthly over 4 years; RSUs vest 50% on each of two consecutive anniversaries.
Full acceleration of awards if termination without cause or for good reason occurs within one year after a change-in-control event.
Exercise price of options equals the closing stock price on the Nasdaq on the grant date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.